Early Prediction of Necrotizing Pneumonia in Children with Mycoplasma Pneumoniae Pneumonia: Development and Temporal Validation of a Clinical Model

肺炎支原体肺炎患儿坏死性肺炎的早期预测:临床模型的建立和时间验证

阅读:1

Abstract

HIGHLIGHTS: What are the main findings? We developed and temporally validated a five-predictor model for necrotizing pneumonia in children hospitalized with Mycoplasma pneumoniae pneumonia using routinely available early clinical data. The model showed good discriminatory performance in both the development cohort and the later validation cohort, supporting its potential use for early risk stratification. What are the implications of the main findings? This model may help identify children at higher risk before overt necrotizing changes become evident on imaging, which may support closer monitoring and earlier reassessment. Because it relies on routinely available variables, the model may be more feasible for future clinical translation, although further external validation is still required. ABSTRACT: Background: Necrotizing pneumonia is a severe complication of Mycoplasma pneumoniae pneumonia (MPP) in children. Early recognition remains challenging because initial clinical manifestations are often non-specific, highlighting the need for a practical tool for early risk stratification. Methods: We conducted a single-center retrospective study of hospitalized children with MPP. Data from 2015–2023 were used for model development, and patients enrolled in 2024 were reserved for temporal validation. We compared candidate machine-learning algorithms and selected a parsimonious random forest model using routinely available variables obtained during the early hospitalization period. Model performance was evaluated using discrimination, calibration, and decision curve analysis, and model interpretability was assessed using SHapley Additive exPlanations (SHAP). Results: The random forest model showed good discriminatory performance in internal validation and retained acceptable performance in the 2024 temporal cohort. Calibration indicated reasonable agreement between predicted and observed risks. Decision curve analysis suggested potential clinical value as a supportive tool for early risk stratification. SHAP analysis highlighted fever duration, C-reactive protein, pleural effusion, alanine aminotransferase, and gamma-glutamyl transferase as the main contributors to model prediction. Conclusions: We developed and temporally validated a clinical prediction model for necrotizing pneumonia in children hospitalized with MPP. The model may support early risk stratification using routinely available clinical data, but it is intended to complement rather than replace clinical judgment. External prospective validation is required before routine clinical implementation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。